Myeloid suppressor cells require membrane tnfr2 expression for suppressive activity

Immunity, Inflammation and Disease

Volumn 2, Issue 2, 2014, Pages 121-130

  Polz, Johannes ^a   Remke, Annika ^a   Weber, Sabine ^a   Schmidt, Dominic ^a   Weber Steffens, Dorothea ^a   Pietryga Krieger, Anne ^a   Müller, Nils ^a   Ritter, Uwe ^a   Mostböck, Sven ^a   Männel, Daniela N ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Immune suppression; Inflammation; Tumor necrosis factor

Indexed keywords

EID: 84948961986     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.19     Document Type: Article

References (32)

1. Feldmann, M., R. N. Maini, 2003. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9:1245–1250.
2. Van Hauwermeiren, F., R. E. Vandenbroucke, C. Libert, 2011. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 22:311–319.
3. Cope, A. P., R. S. Liblau, X. D. Yang, M. Congia, C. Laudanna, R. D. Schreiber, L. Probert, G. Kollias, H. O. McDevitt, 1997. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 185:1573– 1584.
4. Chen, X., M. B€aumel, D. N. M€annel, O. M. Howard, J. J. Oppenheim, 2007. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4þ CD25þ T regulatory cells. J. Immunol. 179:154–161.
5. Chen, X., X. Wu, Q. Zhou, O. M. Howard, M. G. Netea, J. J. Oppenheim, 2013. TNFR2 is critical for the stabilization of the CD4þ Foxp3þ regulatory T cell phenotype in the inflammatory environment. J. Immunol. 190:1076–1084.
6. Sade-Feldman, M., J. Kanterman, E. Ish-Shalom, M. Elnekave, E. Horwitz, M. Baniyash, 2013. Tumor Necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. DOI:10.1016/j.immuni.2013.02.007
7. Zhao, X., L. Rong, X. Zhao, X. Li, X. Liu, J. Deng, H. Wu, X. Xu, U. Erben, P. Wu, 2012. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122:4094–4104.
8. Delano, M. J., P. O. Scumpia, J. S. Weinstein, D. Coco, S. Nagaraj, K. M. Kelly-Scumpia, K. A. OMalley, J. L. Wynn, S. Antonenko, S. Z. AlQuran, 2007. MyD88-dependent expansion of an immature GR-1(þ)CD11b(þ) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204:1463–1474.
9. Youn, J. I., S. Nagaraj, M. Collazo, D. I. Gabrilovich, 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791–5802.
10. Schmid, M., A. K. Wege, U. Ritter, 2012. Characteristics of Tip-DCs and MDSCs and their potential role in leishmania-sis. Front Microbiol. 3:74.
11. Gabrilovich, D. I., S. Nagaraj 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162–174.
12. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, G. Schuler, 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77–92.
13. Naik, S. H., 2008. Demystifying the development of dendritic cell subtypes, a little. Immunol. Cell Biol. 86:439–452.
14. Rossner, S., C. Voigtlander, C. Wiethe, J. Hanig, C. Seifarth, M. B. Lutz, 2005. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 35:3533–3544.
15. Bunt, S. K., L. Yang, P. Sinha, V. K. Clements, J. Leips, S. Ostrand-Rosenberg, 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67:10019–10026.
16. Sander, L. E., S. D. Sackett, U. Dierssen, N. Beraza, R. P. Linke, M. Muller, J. M. Blander, F. Tacke, C. Trautwein, 2010. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med. 207:1453–1464.
17. Chen, X., J. J. Subleski, H. Kopf, O. M. Howard, D. N. M€annel, J. J. Oppenheim, 2008. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4þ CD25þ FoxP3þ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J. Immunol. 180:6467– 6471.
18. Chen, X., J. J. Oppenheim, 2010. TNF-alpha: an activator of CD4þ FoxP3þ TNFR2þ regulatory T cells. Curr. Dir. Autoimmun. 11:119–134.
19. Zhao, X., M. Mohaupt, J. Jiang, S. Liu, B. Li, Z. Qin, 2007. Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis. Cancer Res. 67:4443–4450.
20. Angulo, I., J. Rullas, J. A. Campillo, E. Obregon, A. Heath, M. Howard, M. A. Munoz-Fernandez, J. L. Subiza, 2000. Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-gamma stimulation through a mechanism dependent on endogenous TNF-alpha and IL-1alpha. Eur. J. Immunol. 30:1263–1271.
21. Gabrilovich, D. I., S. Ostrand-Rosenberg, V. Bronte, 2012. Coordinated regulation of myeloid cells by tumors. Nat. Rev. Immunol. 12:253–268.
22. Martin, E. M., A. Remke, E. Pfeifer, J. Polz, A. Pietryga-Krieger, D. Steffens-Weber, M. A. Freudenberg, S. Mostb€ock, D. N. M€annel, 2013. TNFR2 maintains adequate IL-12 production by dendritic cells in inflammatory responses by regulating endogenous TNF levels. Innate. Immun. DOI:10.1177/1753425913506949
23. Ebach, D. R., T. E. Riehl, W. F. Stenson, 2005. Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock 23:311–318.
24. Arnott, C. H., K. A. Scott, R. J. Moore, S. C. Robinson, R. G. Thompson, F. R. Balkwill, 2004. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902–1910.
25. Sterns, T., N. Pollak, B. Echtenacher, D. N. M€annel, 2005. Divergence of protection induced by bacterial products and sepsis-induced immune suppression. Infection and Immunity 73:4905–4912.
26. Echtenacher, B., D. N. M€annel, 2002. Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis. J. Endotoxin. Res. 8:365–369.
27. Vaknin, I., L. Blinder, L. Wang, R. Gazit, E. Shapira, O. Genina, M. Pines, E. Pikarsky, M. Baniyash, 2008. A common pathway mediated through Toll-like receptors leads to T-and natural killer-cell immunosuppression. Blood 111:1437– 1447.
28. Erickson, S. L., F. J. de Sauvage, K. Kikly, K. Carver-Moore, S. Pitts-Meek, N. Gillett, K. C. Sheehan, R. D. Schreiber, D. V. Goeddel, M. W. Moore, 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372:560–563.
29. Shen, F. W., Y. Saga, G. Litman, G. Freeman, J. S. Tung, H. Cantor, E. A. Boyse, 1985. Cloning of Ly-5 cDNA. Proc. Natl. Acad. Sci. USA 82:7360–7363.
30. Korner, H., M. Cook, D. S. Riminton, F. A. Lemckert, R. M. Hoek, B. Ledermann, F. Kontgen, B. Fazekas de St. Groth, J. D. Sedgwick, 1997. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur. J. Immunol. 27:2600– 2609.
31. Echtenacher, B., W. Falk, D. N. M€annel, P. H. Krammer, 1990. Requirement of endogenous tumor-necrosis-factor cachectin for recovery from experimental peritonitis. J. Immunol. 145:3762–3766.
32. Pollak, N., T. Sterns, B. Echtenacher, D. N. M€annel, 2005. Improved resistance to bacterial superinfection in mice by treatment with macrophage migration inhibitory factor. Infect. Immun. 73:6488–6492.